Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v2-EN
Language French English
Date Updated 2019-12-07 2019-11-23
Drug Identification Number 00884502 00884502
Brand name LUPRON DEPOT LUPRON DEPOT
Common or Proper name Lupron depot 3.75mg Lupron depot 3.75mg
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients LEUPROLIDE ACETATE LEUPROLIDE ACETATE
Strength(s) 3.75MG 3.75MG
Dosage form(s) POWDER FOR SUSPENSION, SUSTAINED-RELEASE POWDER FOR SUSPENSION, SUSTAINED-RELEASE
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 syringe (3.75mg) 1 syringe (3.75mg)
ATC code L02AE L02AE
ATC description HORMONES AND RELATED AGENTS HORMONES AND RELATED AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-11-21 2019-11-21
Actual start date 2019-11-21 2019-11-21
Estimated end date 2019-12-06 2019-12-06
Actual end date 2019-12-06
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments We are pleased to share that this dossier has been resolved as per expected due date and orders are now being processed as per our normal process. Thank you for your continued partnership This drug shortage is the result of a precautionary hold that was instituted for product within AbbVie control. AbbVie strives to maintain an uninterrupted supply of products and will continue to keep this site updated on this situation. In the meantime to fulfill your immediate needs, you can purchase your preferred dose through a wholesaler.
Health Canada comments